GIÁ TRỊ CỦA NỒNG ĐỘ PSA TRONG CHẨN ĐOÁN UNG THƯ TUYẾN TIỀN LIỆT

Abstract

Objectives: To evaluate the diagnostic value of PSA (Prostate-Specific Antigen) concentrations for prostate cancer in patients undergoing prostate biopsy. Methods: A cross-sectional descriptive study was conducted on 81 patients who underwent transrectal ultrasound-guided prostate biopsy with histopathological results at Viet Duc University Hospital from March 2023 to October 2023. The correlation of total PSA, free PSA, % free PSA, and PSA density with histopathological results defined as prostate cancer (Gleason score ≥ 6) was analyzed. Results: The mean values of total PSA, free PSA, and PSA density in the prostate cancer group were 90.8 ± 69.16 ng/mL, 10.9 ± 8.29 ng/mL, and 2.30 ± 2.24 ng/mL/mL, respectively, which were higher than those in the non-prostate cancer group (26.6 ± 17.73 ng/mL, 3.7 ± 3.42 ng/mL, and 0.47 ± 0.32 ng/mL/mL, respectively), with p < 0.01. Furthermore, the diagnostic value of total PSA for prostate cancer showed a cut-off point of 57 ng/mL, AUC = 0.803, Se 62.5%, Sp 94.9%, PPV 59.5%, NPV 94.9% (p < 0.01). For free PSA, the cut-off point was 6.2 ng/mL, with AUC = 0.769, Se 72.5%, Sp 87.2%, PPV 69.0%, and NPV 87.2% (p < 0.01). For PSA density, the cut-off point was 1.2 ng/mL/mL, with AUC = 0.849, Se 67.5%, Sp 76%, PPV 64.3%, and NPV 97.4% (p < 0.01). Conclusion: Total PSA levels, along with free PSA and PSA density, contribute to increasing the diagnostic value for prostate cancer.